The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer’s disease. Approval was based on a 48-week ...

ZURICH, Sept 24 (Reuters) - The European Union has approved Novartis's Exelon skin patch to treat Alzheimer's disease, the Swiss drugmaker said on Monday. "The European Commission has approved Exelon ...

Breckenridge has received the Food and Drug Administration’s green light for rivastigmine transdermal system in dosage strengths of 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours. The product is ...

A transdermal patch formulation of Novartis’ Alzheimer’s disease drug Exelon seems to offer the same efficacy as the current capsule formulation of the drug, and could make it easier for doctors to ...

According to the World Health Organization (WHO), an estimated 50 million people are living with dementia globally. This number is projected to increase to 82 million by 2030 and over 150 million by ...

Co announces Exelon Patch has received its first worldwide approval in the U.S. as a way to deliver an effective medicine for mild to moderate Alzheimer's disease patients through a skin patch instead ...

Alzheimer’s patients may soon get the first skin patch to treat the creeping brain degeneration, a novel way to deliver an older drug so that it’s easier to take and might even work a little better.

WASHINGTON – Alzheimer’s patients may soon get the first skin patch to treat the creeping brain degeneration, a novel way to deliver an older drug so that it’s easier to take and might even work a ...

DUBLIN — Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine ...